PDF
ePub
Citation
Print
Abstract
Purpose
This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002.
Methods
Eight hundred and eighty three subjects aged ≥6 months received a single dose of the vaccine; an additional dose was administered to those aged <9 years and unprimed with an influenza vaccine. Four hundred and eleven subjects used diary cards to record safety information; this report presents data from these subjects. Incidence of solicited local, general and unsolicited adverse events (4-days and 21-days post-vaccination follow-up periods, respectively) were recorded. Serious adverse events (SAEs) were recorded throughout the study period.
Results
Injection site pain (subjects aged <6 years: 12.6% of subjects, ≥6 years: 34.7%), fever (<6 years: 1.3%) and myalgia (≥6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by ≤4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria).
Conclusion
Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.
References
1. World Health Organization (WHO). Position Paper Influenza Vaccines. Wkly Epidemiol Rec. 2005. 80:277–288.
2. Influenza overview. World Health Organization (WHO). Accessed: 18 May 2010. Available: http://www.who.int/mediacentre/factsheets/2003/fs211/en/.
3. Rose GW, Cooper CL. Fluarix™, inactivated split-virus influenza vaccine. Expert Opin Biol Ther. 2006. 6:301–310.
4. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine. 2008. 26S:D17–D22.
5. Tilburt JC, Mueller PS, Ottenberg AL, Poland GA, Koenig BA. Facing the challenges of influenza in healthcare settings: The ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine. 2008. 26S:D27–D30.
6. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootray G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009. 58(RR-8):1–52.
7. Kim SH, Huh JH, Bae SY, Kim JS, Yoon SY, Lim CS, et al. Epidemiology of respiratory viral infection in 2004-2006. Korean J Lab Med. 2006. 26:351–357.
8. Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respiratory tract infections in Korean children. J Infect. 2000. 41:152–158.
9. Kim YK, Nyambat BH, Hong YS, Lee CG, Lee JW, Kilgore PE. Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect Dis. 2008. 40:946–953.
10. Chun BC, Woo HJ, Park SC. Preventive efficacy of influenza vaccination against to influenza-like illness among eldery. Korean J Epidemiol. 1999. 21:205–219.
11. Lee HJ. Classification of vaccination and immunization schedule recommended by the Korean Pediatric Society, 2008. J Korean Med Assoc. 2008. 51:104–109.
12. Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, et al. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect. 2007. 55:273–281.
13. The Korean Pediatric Society. Kang JH. [Influenza]. Immunization Guideline. 2002. 5th ed. Seoul: The Korean Pediatric Society;136–154.
14. Seo JJ, Kim MJ, Kim SH, Kee HY, Chung JK, Kim ES, et al. Characterization of respiratory viral infection in children in Gwangju. Infect Chemother. 2008. 40:218–229.
15. Lee JS, Shin KC, Na BK, Lee JY, Kang C, Kim JH, et al. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect. 2007. 135:1117–1123.
16. Nah SY, Park SE, Park JY, Lee HJ. Epidemiology of influenza virus over 8 years (1990-1998) in Seoul, Korea. Korean J Infect Dis. 1999. 31:210–216.
17. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med. 1973. 288:498–505.
18. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin. 2005. 1:239–244.
19. Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest. 2002. 22:751–769.
20. El Sahly HM, Keitel WA. Clinical data on Fluarix™: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008. 7:713–719.
21. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008. 359:1555–1564.
22. Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A. Cross-Protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology. 2007. 50:58–62.
XML Download